Recent events
Recent events tied to this brand in public sources.
Back to profile19 entries
2026
Regeneron extends U.S. agreement for additional Ebola treatment supply
Regeneron extended a U.S. agreement for additional supply of an Ebola treatment.
2026
Regeneron presents 44-month Libtayo follow-up data
Regeneron presented a 44-month follow-up update on Libtayo in patients with high-risk skin cancer at the European Society for Medical Oncology Congress in Madrid. The reported estimated death hazard ratio was 0.63 versus placebo, but its 95% confidence interval crossed 1.0, so the update did not establish a statistically significant overall-survival advantage.
2026
Sanofi expands Regeneron partnership with deal worth up to $8 billion
Reuters reported that Sanofi expanded its partnership with Regeneron through a deal worth up to $8 billion, described as a win for Sanofi's new chief executive.
2021
Amgen files Supreme Court petition in patent dispute
Amgen Inc. and its subsidiaries filed a petition for certiorari with the U.S. Supreme Court against Sanofi Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US, LLC. The petition concerns the written-description requirement for patents and the level of detail required.
2021
Humana sues Regeneron over alleged Eylea pricing scheme
Humana filed suit against Regeneron, alleging that Regeneron and the Chronic Disease Foundation engaged in a scheme involving Eylea that defrauded Medicare and its contracted payors. The complaint alleged that Regeneron inflated Eylea's price and provided illegal kickbacks to the foundation; these are allegations, not a stated court finding.
2021
Shareholder advisers criticize Regeneron executive payouts
Shareholder advisory groups Glass Lewis and Institutional Shareholder Services criticized Regeneron’s upfront executive stock awards as excessive and questioned whether they were in shareholders’ best interests. The article also reports substantial shareholder opposition to the company’s executive payouts in recent years.
2021
FDA approves Evkeeza for HoFH
The U.S. Food and Drug Administration approved Regeneron’s Evkeeza as an adjunct to other LDL-C-lowering therapies for adult and pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia.
2021
FDA approves Regeneron’s evinacumab
The FDA approved Regeneron’s drug evinacumab as an addition to other cholesterol-lowering therapies for adults and children older than 12 with homozygous familial hypercholesterolemia. The drug will be marketed under the name Evkeeza.
2021
FDA approves Libtayo for advanced basal cell carcinoma
The U.S. FDA approved Libtayo for patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom such treatment is not appropriate; approval was full for locally advanced disease and accelerated for metastatic disease.
2020
Regeneron challenges federal drug-pricing rule
Regeneron Pharmaceuticals filed a complaint against the Department of Health and Human Services and other federal defendants, challenging a drug-pricing rule and alleging, among other claims, that it was issued without the notice-and-comment period required by the Administrative Procedures Act.
2020
Sanofi stops Kevzara COVID-19 clinical trials
Sanofi stopped clinical trials of Kevzara for COVID-19 after tests found adverse effects, including pneumonia and death in some patients. The company said it no longer planned further COVID-19 clinical studies of the drug.
2020
Regeneron announces pricing of $2 billion notes offering
Regeneron announced pricing for an underwritten offering of $1.25 billion in senior unsecured notes due 2030 and $750 million due 2050. The announcement said issuance was expected to close around August 12, 2020, subject to customary closing conditions.
2020
BioNTech and Regeneron announce melanoma trial collaboration
BioNTech announced a strategic collaboration with Regeneron for a clinical trial combining BioNTech's BNT111 FixVac candidate and Regeneron's Libtayo for melanoma. The companies said they planned to jointly conduct a randomized Phase 2 study and share the trial's development costs equally.
2020
U.S. sues Regeneron over alleged Eylea kickbacks
The U.S. Justice Department sued Regeneron, accusing the company of making kickback payments related to Eylea through a copay foundation. The case alleges false claims and seeks treble damages; the allegations are not established as findings in this article.
2020
DOJ files civil lawsuit against Regeneron over patient charity payments
The US Department of Justice filed a civil lawsuit against Regeneron, alleging that the company illegally paid a patient group to cover costs for Medicare patients receiving its Eylea treatment. Regeneron said the allegations had no merit and that it would defend the case.
2020
Sanofi completes sale of most of its Regeneron stake
Sanofi completed the sale of 13.0 million Regeneron shares and said it had sold its entire equity investment in Regeneron, excluding 400,000 shares it retained, for total gross proceeds of $11.7 billion.
2020
Regeneron announces pricing of Sanofi secondary share offering and planned repurchase
Regeneron announced pricing for an underwritten secondary offering of 11,831,496 shares held by Sanofi at $515 per share, and agreed to purchase 9,806,805 shares directly from Sanofi for $5 billion. The release describes the transactions; it does not establish their completion.
2020
PTAB rejects challenges to four Kymab patents
The US Patent Trial and Appeal Board declined to proceed with inter partes review proceedings requested by Regeneron concerning four Kymab patents, leaving those challenges unsuccessful.
2020
Zai Lab and Regeneron partner on REGN1979 in Greater China
Zai Lab and Regeneron announced a strategic collaboration to develop and commercialize REGN1979 in mainland China, Hong Kong, Taiwan and Macau. Zai Lab received development and exclusive commercialization rights in the oncology field in those markets; Regeneron will manufacture and supply the product for the region.